Yüklüyor......
Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
Low dose metronomic (LDM) chemotherapy has shown promising activity in many preclinical and some phase II clinical trials involving various tumor types. To evaluate the potential therapeutic impact of LDM chemotherapy for ovarian cancer, we developed a preclinical model of advanced disease and teste...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2010
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2852477/ https://ncbi.nlm.nih.gov/pubmed/20371722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-09-0960 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|